Global Nucala Market 2026–2035 expanding with respiratory biologics

The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

What Is The Estimated Market Size Of The Nucala Market During 2026–2030?

Historical growth has been driven by an escalating occurrence of severe eosinophilic asthma, enhanced recognition of eosinophilic disorders, the broadening of biologic treatment guidelines, advancements in diagnostic testing for eosinophil levels, and expanding specialist prescribing practices.

Growth during the projected period is expected due to the expanding use in new eosinophilic conditions, a growing need for customized respiratory biologics, progress in monoclonal antibody engineering, more extensive global reimbursement opportunities, and the greater embrace of at-home treatment options.

Key developments anticipated in the forecast period encompass the increasing integration of targeted biologic therapies for asthma, the expanded application of IL-5 inhibitors in managing chronic conditions, the broader implementation of precision medicine techniques in respiratory treatment, an elevated focus on achieving sustained disease management, and refined practices for patient segmentation.

Download the Free Sample Report to Explore Key Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=20300&type=smp

What Underlying Factors Are Accelerating The Growth Of The Nucala Market?

The Nucala market is expected to grow due to the increasing prevalence of asthma. Asthma is a chronic respiratory condition characterized by inflammation and narrowing of the airways, leading to symptoms like wheezing, coughing, chest tightness, and shortness of breath, often triggered by allergens or physical activity. The rise in asthma cases is attributed to environmental pollution, allergens, lifestyle changes, urbanization, and genetic predisposition. Nucala works by targeting and inhibiting interleukin-5 (IL-5), a key protein responsible for the growth and activation of eosinophils. These white blood cells contribute to airway inflammation in asthma, and Nucala’s action reduces both symptoms and the frequency of asthma exacerbations. For example, in February 2023, NHS England, a UK-based government department, indicated that 5.4 million people in the UK receive asthma treatment, with approximately 160,000 new diagnoses annually, and work-related asthma accounts for 9-15% of adult-onset cases. Thus, the growing prevalence of asthma is a significant driver for the Nucala market.

How Are The Various Segments Of The Nucala Market Categorized?

The nucala market covered in this report is segmented –

1) By Indication: Severe Asthma, Eosinophilic Granulomatosis With Polyangiitis (EGPA), Chronic Obstructive Pulmonary Disease (COPD), Other Eosinophilic Disorders

2) By Distribution Channel: Direct Sales, Retail Pharmacies, Online Pharmacies

3) By End User: Hospitals, Clinics, Home Care Settings

What Trends Are Affecting The Expansion Of The Nucala Market?

Leading firms within the Nucala market are concentrating their efforts on creating advanced solutions, including ready-to-use injectable formulations, in response to the growing need for easier patient access and better adherence to treatment regimens. Such an injectable form refers to a pharmaceutical product that is pre-manufactured and does not necessitate additional dilution or mixing prior to its use. As an illustration, in May 2025, GlaxoSmithKline Plc, a pharmaceutical entity based in the UK, secured approval from the US FDA for its drug Nucala (mepolizumab), intended for adults suffering from chronic obstructive pulmonary disease (COPD) characterized by an eosinophilic phenotype. This broadening of the approved use facilitates focused treatment for COPD patients who have significant unmet medical requirements, substantiated by favorable outcomes from the MATINEE and METREX Phase III trials.

Which Major Firms Influence Developments In The Nucala Market?

Major companies operating in the nucala market are GlaxoSmithKline plc

Read the full nucala market report here:

https://www.thebusinessresearchcompany.com/report/nucala-global-market-report

Which Region Is Projected To Dominate The Nucala Market During The Forecast Period?

North America was the largest region in the nucala market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the nucala market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Tailored Nucala Market Research Report For Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=20300&type=smp

Browse Through More Reports Similar to the Global Nucala Market 2026, By The Business Research Company

Inductor Market Market Report 2026

https://www.thebusinessresearchcompany.com/report/inductor-market-global-market-report

Vertical Market Software Market Report 2026

https://www.thebusinessresearchcompany.com/report/vertical-market-software-global-market-report

Data Lake Market Report 2026

https://www.thebusinessresearchcompany.com/report/data-lake-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795